← Back to Search

Other

VX-548 for Acute Pain

Phase 3
Waitlist Available
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 2 up to day 14
Awards & highlights

Study Summary

This trial will test a new drug to see if it can safely and effectively treat acute pain.

Who is the study for?
This trial is for adults with a BMI between 18.0 and 40.0 who are experiencing new, moderate to severe acute pain, rated ≥4 on the numeric scale. It includes both surgical patients with postoperative pain and non-surgical individuals with new pain not related to any known condition.Check my eligibility
What is being tested?
The study is testing VX-548's safety and effectiveness in treating acute pain. Participants will receive VX-548 under controlled conditions to assess how well it manages their pain symptoms.See study design
What are the potential side effects?
While specific side effects of VX-548 are not listed here, common side effects from medications treating acute pain may include nausea, dizziness, headache, or drowsiness. Individual reactions can vary.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 2 up to day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 2 up to day 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Secondary outcome measures
Proportion of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA)

Trial Design

1Treatment groups
Experimental Treatment
Group I: VX-548Experimental Treatment1 Intervention
Participants will receive VX-548 every 12 hours (q12h) up to 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VX-548
2022
Completed Phase 3
~3500

Find a Location

Who is running the clinical trial?

Vertex Pharmaceuticals IncorporatedLead Sponsor
243 Previous Clinical Trials
32,129 Total Patients Enrolled
14 Trials studying Pain
832 Patients Enrolled for Pain

Media Library

VX-548 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05661734 — Phase 3
Pain Research Study Groups: VX-548
Pain Clinical Trial 2023: VX-548 Highlights & Side Effects. Trial Name: NCT05661734 — Phase 3
VX-548 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05661734 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has VX-548 been sanctioned by the FDA for medical use?

"Our experts at Power gave VX-548 a rating of 3 on the safety scale due to numerous rounds of data that have demonstrated its efficacy and security."

Answered by AI

Are individuals who are youthful than 70 years of age qualified for this research?

"This medical experiment has specific inclusion criteria that necessitate the patient be within the age range of 18 to 80. For those younger than 18, there are 86 trials and 353 for older adults exceeding 65 years old."

Answered by AI

Does my medical profile qualify me to partake in this experiment?

"To be eligible for this medical research, potential participants must display symptoms of pain and fall between the ages 18-80. As there are 250 spots available, applications will be reviewed on a first come first served basis."

Answered by AI

Has enrollment for this trial opened yet?

"Patients are being sought for this clinical trial. It was first listed on the 9th of January, 2023 and has been most recently updated by its research team 11 days later."

Answered by AI

How many participants is this clinical trial accommodating?

"Confirmed. According to clinicaltrials.gov, recruitment for this medical trial commenced on the 9th of January in 2023 and was updated recently on 11th of January in the same year. 250 participants are being enrolled at two different sites."

Answered by AI

Who else is applying?

What state do they live in?
Texas
California
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
3+
What site did they apply to?
Trovare Clinical Research | Bakersfield, CA
Anaheim Clinical Trials
Atlanta Center for Medical Research | Atlanta, GA
Other

How responsive is this trial?

Most responsive sites:
  1. Anaheim Clinical Trials: < 48 hours
Typically responds via
Phone Call
Average response time
  • < 2 Days
~115 spots leftby Apr 2025